Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase

ConclusionThis study supports the current recommendation for cautious use of tofacitinib in patients with high thromboembolic risk. Moreover, with a similar patient profile and elevated reporting for baricitinib, a potential class effect of JAK inhibitors cannot be ruled out.

http://link.springer.com/10.1007/s40264-020-00958-9

Source: Drug Safety - June 11, 2020 Category: Drugs & Pharmacology Source Type: research